We have located links that may give you full text access.
Alexithymia Predicts Cognitive Deficits In Patients With Idiopathic Parkinson's Disease.
Journal of Ayub Medical College, Abbottabad : JAMC 2019 January
BACKGROUND: In recent years, alexithymia has gained attention of medical researchers as a prognostic factor for serious health problems. The present study aimed to assess alexithymia as a determinant of cognitive decline in patients with Parkinson's disease..
AIM: The aim of our study is to assess the pain relief after CPN, reduction in analgesics consumption and evaluation of patient satisfaction post procedure.
METHODS: Patients diagnosed with Parkinson's disease (n=60) at Bahawal Victoria Hospital, Civil Hospital Bahawalpur and Nishter Hospital Multan during May 2016 until June 2017 participated in the study. Healthy individuals (n=60) took part in the study from local community as controls. Participants completed Bermond-Vorst Alexithymia Questionnaire and Montreal Cognitive Assessment. It was a cross sectional study design. Purposive sampling technique was used and data was analysed through multivariate analysis of variance and bivariate correlation.
RESULTS: Patients with Parkinson's disease (177.96±8.93) showed higher attitudes of alexithymia as compared with healthy individuals (37.46±8.01), F (1,118) = 8216.52, p<0.001, ηp2=.98. In contrast with healthy controls (28.60±0.58), patients with Parkinson's disease (2.25±.95) were cognitively impaired F (1,118) =36424.38, p<0.001, ηp2=.99. Alexithymia was a significant predictor of cognitive performance (R2=0.99, F (2, 119) = 5698.95, p<0.001).
CONCLUSIONS: Alexithymia is a significant marker of cognitive decline in patients with Parkinson's disease.
AIM: The aim of our study is to assess the pain relief after CPN, reduction in analgesics consumption and evaluation of patient satisfaction post procedure.
METHODS: Patients diagnosed with Parkinson's disease (n=60) at Bahawal Victoria Hospital, Civil Hospital Bahawalpur and Nishter Hospital Multan during May 2016 until June 2017 participated in the study. Healthy individuals (n=60) took part in the study from local community as controls. Participants completed Bermond-Vorst Alexithymia Questionnaire and Montreal Cognitive Assessment. It was a cross sectional study design. Purposive sampling technique was used and data was analysed through multivariate analysis of variance and bivariate correlation.
RESULTS: Patients with Parkinson's disease (177.96±8.93) showed higher attitudes of alexithymia as compared with healthy individuals (37.46±8.01), F (1,118) = 8216.52, p<0.001, ηp2=.98. In contrast with healthy controls (28.60±0.58), patients with Parkinson's disease (2.25±.95) were cognitively impaired F (1,118) =36424.38, p<0.001, ηp2=.99. Alexithymia was a significant predictor of cognitive performance (R2=0.99, F (2, 119) = 5698.95, p<0.001).
CONCLUSIONS: Alexithymia is a significant marker of cognitive decline in patients with Parkinson's disease.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices 
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app